Login to Your Account

Financings Roundup

Logical's Series B Adds $30M To Advance NSAID Prodrug

By Jennifer Boggs

Thursday, June 14, 2007
Logical Therapeutics Inc., which develops drugs for diseases associated with or caused by inflammation, raised $30 million in its Series B round to push its early stage pipeline through proof-of-concept trials, starting with a naproxen prodrug aimed at chronic pain.(BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription